European shares fall: Trump threatens ’massive’ tariff increase on China
Investing.com - BioNTech (NASDAQ:BNTX) shares surged 10% on Friday following positive results from a Phase 3 trial of its anti-HER2 antibody drug conjugate in breast cancer patients. The $26.92 billion market cap company, which maintains a strong balance sheet with more cash than debt and a healthy current ratio of 8.61, continues to demonstrate its commitment to oncology innovation.
The company announced that its BNT323/DB-1303 (trastuzumab pamirtecan) treatment outperformed trastuzumab emtansine (KADCYLA) on the primary endpoint of progression-free survival in a Chinese study of patients with HER2+ metastatic or unresectable breast cancer.
BioNTech’s partner DualityBio, which conducted the trial, plans to approach Chinese regulators to discuss approval based on the interim data. BioNTech holds global commercial rights outside of China and is currently conducting a global Phase 3 study in HER2-low metastatic breast cancer.
Clear Street reiterated its Buy rating on BioNTech with a $185.00 price target following the news. The firm noted that the positive results align with its thesis that BioNTech is building an integrated oncology pipeline centered on next-generation immuno-oncology agents that can be combined with in-house ADCs. According to InvestingPro data, analyst targets range from $112.80 to $173.77, with the stock currently trading near its Fair Value.
BioNTech’s stock performance outpaced the broader biotech sector on Friday, with the Nasdaq Biotechnology Index rising just 2% compared to BioNTech’s 10% gain. Get deeper insights into BioNTech and other biotech companies with InvestingPro, featuring comprehensive financial health scores and exclusive analysis of 1,400+ stocks.
In other recent news, BioNTech has reported significant developments in its ongoing projects and financial performance. The company announced that its experimental cancer drug, trastuzumab pamirtecan, met its primary endpoint of progression-free survival in a pivotal Phase 3 trial for HER2-positive breast cancer. This positive outcome has led BMO Capital to maintain an Outperform rating on BioNTech, with a price target of $143.00. Meanwhile, H.C. Wainwright lowered its price target for BioNTech to $136, citing increased operating expenses and a net loss of €1.60 per diluted share for the second quarter of 2025, which fell short of their earnings forecast.
BioNTech’s quarterly revenue of €339.0 million also missed H.C. Wainwright’s estimate of €1,725.9 million. In contrast, TD Cowen raised its price target to $120.00 from $110.00, highlighting BioNTech’s second-quarter Comirnaty sales of €153 million, which surpassed both consensus estimates and the firm’s own projections. Additionally, Wells Fargo adjusted its price target to $150.00 from $170.00, reflecting updates related to BioNTech’s collaboration with Bristol Myers Squibb. These recent developments provide investors with a range of insights into BioNTech’s current financial and operational status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.